CA2378898A1 - Procede de mesure de l'activite du facteur coagulant - Google Patents
Procede de mesure de l'activite du facteur coagulant Download PDFInfo
- Publication number
- CA2378898A1 CA2378898A1 CA002378898A CA2378898A CA2378898A1 CA 2378898 A1 CA2378898 A1 CA 2378898A1 CA 002378898 A CA002378898 A CA 002378898A CA 2378898 A CA2378898 A CA 2378898A CA 2378898 A1 CA2378898 A1 CA 2378898A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitor
- whole blood
- blood
- sample
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne des procédés d'évaluation rapide des propriétés coagulantes globales d'un échantillon sanguin d'un patient, qui consistent à mesurer et à comparer le temps de coagulation avec et sans inhibiteur ajouté d'un procoagulant ou d'un anticoagulant. Lorsque l'échantillon est constitué de sang entier, le temps de coagulation résultant représente l'activité coagulante globale du plasma et des composants cellulaires du sang, laquelle est représentative d'une pathologie existante ou imminente découlant d'une coagulabilité anormale. L'invention porte également sur un procédé de mesure du risque chez un patient d'événement thrombotique, par la détermination des taux courants au plan fonctionnel de procoagulant(s) ou d'anticoagulant(s) dans le sans entier. Par ailleurs, une méthode de mesure de l'efficacité d'une thérapie anticoagulante est décrite ainsi que des kits pour la mise en oeuvre de la méthode de l'invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14514099P | 1999-07-23 | 1999-07-23 | |
US60/145,140 | 1999-07-23 | ||
PCT/US2000/020118 WO2001007070A1 (fr) | 1999-07-23 | 2000-07-24 | Procede de mesure de l'activite du facteur coagulant |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2378898A1 true CA2378898A1 (fr) | 2001-02-01 |
Family
ID=22511767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002378898A Abandoned CA2378898A1 (fr) | 1999-07-23 | 2000-07-24 | Procede de mesure de l'activite du facteur coagulant |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1212073A4 (fr) |
JP (1) | JP2003505678A (fr) |
KR (1) | KR20020042622A (fr) |
CN (1) | CN1368886A (fr) |
AU (1) | AU6369700A (fr) |
CA (1) | CA2378898A1 (fr) |
WO (1) | WO2001007070A1 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6743596B1 (en) * | 2000-10-27 | 2004-06-01 | Biomerieux, Inc. | Method of determining global coagulability hemostatic potential |
US20030064414A1 (en) * | 2001-03-30 | 2003-04-03 | Benecky Michael J. | Rapid assessment of coagulation activity in whole blood |
DE102005005824A1 (de) * | 2005-02-08 | 2006-08-17 | Zlb Behring Gmbh | Methode zur Differenzierung von Faktor XIII-gegenüber Fibrinogen-Mangelzuständen unter Einsatz thrombelastographischer Techniken |
JP4267592B2 (ja) * | 2005-05-23 | 2009-05-27 | 潤 川崎 | 抗血栓薬薬効試験法 |
CN100434901C (zh) * | 2006-01-12 | 2008-11-19 | 上海交通大学 | 血红蛋白凝胶层析的教学试剂盒 |
CA2641189A1 (fr) * | 2006-01-31 | 2007-08-09 | Mitsubishi Kagaku Iatron, Inc. | Procede pour determiner l'etat d'un syndrome de coagulation intravasculaire disseminee |
GB0701821D0 (en) * | 2007-02-01 | 2007-03-14 | Pentapharm Ag | Diagnostic composition and its use in the determination of coagulation characteristics of a test liquid |
US8574849B2 (en) | 2007-10-03 | 2013-11-05 | The University Of Vermont And State Agriculture College | Methods of detection of factor XIa and tissue factor |
JP5739816B2 (ja) | 2008-12-19 | 2015-06-24 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Tfpiインヒビターおよび使用法 |
NZ603028A (en) | 2010-03-19 | 2014-11-28 | Baxter Healthcare Sa | Tfpi inhibitors and methods of use |
EP2471945A1 (fr) * | 2010-12-30 | 2012-07-04 | Siemens Healthcare Diagnostics Products GmbH | Procédé de détermination d'inhibiteurs de coagulation |
KR102263685B1 (ko) | 2012-03-21 | 2021-06-11 | 다케다 야쿠힌 고교 가부시키가이샤 | Tfpi 저해제 및 사용 방법 |
US20150278470A1 (en) * | 2012-10-25 | 2015-10-01 | Koninklijke Philips N.V. | Combined use of clinical risk factors and molecular markers fro thrombosis for clinical decision support |
EP3470837A1 (fr) | 2013-01-20 | 2019-04-17 | Dyax Corp. | Traitement de troubles dans lesquels intervient pkal |
EP2818871A1 (fr) | 2013-06-28 | 2014-12-31 | Roche Diagniostics GmbH | Moyens et procédés pour étalonnage universel de tests anti-facteur Xa |
CN103604766A (zh) * | 2013-11-25 | 2014-02-26 | 牡丹江友搏药业股份有限公司 | 一种疏血通注射液的生物学质控方法 |
US9452199B2 (en) * | 2014-01-17 | 2016-09-27 | General Electric Company | Platelet activation and growth factor release using electric pulses |
SE540132C2 (sv) * | 2014-05-22 | 2018-04-10 | Zafena Ab | Analysmetod för bestämning av antikoagulanter i blod eller blodplasma |
CN104345154B (zh) * | 2014-08-22 | 2016-10-26 | 北京蛋白质组研究中心 | 一种检测多肿瘤相关“多肽-蛋白组合式标志物”的双抗体夹心试剂盒 |
CN104177503B (zh) * | 2014-08-22 | 2018-04-13 | 北京蛋白质组研究中心 | 一种激酶通路相关“多肽‑蛋白组合式”标志物及定量检测技术 |
CN104698159B (zh) * | 2015-03-10 | 2017-03-08 | 中国科学院苏州生物医学工程技术研究所 | 一种内毒素含量的检测方法 |
CN110192105B (zh) * | 2017-01-06 | 2022-04-12 | 索尼公司 | 凝血系统分析和失血量预测装置、系统、方法和程序 |
US20210263052A1 (en) * | 2018-07-25 | 2021-08-26 | Sony Corporation | Blood coagulation system analysis device |
WO2020190266A1 (fr) * | 2019-03-15 | 2020-09-24 | Coagulation Sciences Llc | Dispositif de test de coagulation, système et procédé d'utilisation |
US10429377B1 (en) | 2019-03-15 | 2019-10-01 | Coagulation Sciences Llc | Coagulation test device, system, and method of use |
KR20210153097A (ko) | 2019-04-16 | 2021-12-16 | 다케다 파머수티컬 컴패니 리미티드 | 기능성 c1 에스테라제 저해제(fc1-inh)의 정량 방법 |
RU2750839C1 (ru) * | 2020-05-18 | 2021-07-05 | Общество с ограниченной ответственностью "Меднорд-Техника" (ООО "Меднорд-Т") | Устройство и способ экспресс-оценки агрегационной активности форменных элементов крови |
JPWO2022145475A1 (fr) * | 2020-12-28 | 2022-07-07 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4814247A (en) * | 1983-01-26 | 1989-03-21 | University Of Medicine And Dentistry Of New Jersey | Method for determining the existance and/or the monitoring of a pathological condition in a mammal |
US4882272A (en) * | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
US5741779A (en) * | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
US5783447A (en) * | 1996-10-02 | 1998-07-21 | University Of Medicine And Dentistry Of New Jersey | Hypercoagulability comparative determinants obtained using detection systems with variable force-induced energy inputs |
EP1084270B1 (fr) * | 1998-06-08 | 2004-08-25 | The University Of Vermont And State Agricultural College | Méthode de mesure de la coagulation dans le plasma |
-
2000
- 2000-07-24 CN CN00810751A patent/CN1368886A/zh active Pending
- 2000-07-24 EP EP00950617A patent/EP1212073A4/fr not_active Withdrawn
- 2000-07-24 CA CA002378898A patent/CA2378898A1/fr not_active Abandoned
- 2000-07-24 KR KR1020027000975A patent/KR20020042622A/ko not_active Application Discontinuation
- 2000-07-24 WO PCT/US2000/020118 patent/WO2001007070A1/fr not_active Application Discontinuation
- 2000-07-24 AU AU63697/00A patent/AU6369700A/en not_active Abandoned
- 2000-07-24 JP JP2001511953A patent/JP2003505678A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1212073A1 (fr) | 2002-06-12 |
WO2001007070A1 (fr) | 2001-02-01 |
EP1212073A4 (fr) | 2003-09-03 |
KR20020042622A (ko) | 2002-06-05 |
JP2003505678A (ja) | 2003-02-12 |
CN1368886A (zh) | 2002-09-11 |
AU6369700A (en) | 2001-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2378898A1 (fr) | Procede de mesure de l'activite du facteur coagulant | |
Lowe et al. | Plasma fibrinogen | |
US5525477A (en) | Method for diagnosing blood clotting disorders | |
US20030064414A1 (en) | Rapid assessment of coagulation activity in whole blood | |
Brummel‐Ziedins et al. | Thrombin generation: phenotypic quantitation | |
US6245573B1 (en) | Rapid assessment of the coagulant activity of blood | |
Lippi et al. | Milestones and perspectives in coagulation and hemostasis | |
US5525478A (en) | Soluble thrombomodulin-based one-stage assay for vitamin-K dependent coagulation-inhibiting proteins | |
EP2235542B1 (fr) | Procédé in vitro de diagnostic pour évaluer la maladie de von willebrand et le risque saignement associé avec la maladie de von willebrand et les troubles acquis ou congénitaux de fonction plaquettaire | |
Simpson et al. | Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults | |
CA2623142A1 (fr) | Methodes de test global de la coagulation et de la fibrinolyse | |
JP3248621B2 (ja) | 血栓症リスクのテスト | |
CA2155503C (fr) | Methode de detection des anomalies de coagulation sanguine a mediation proteique/proteique | |
Hoffmann et al. | Automated nephelometry of fibrinogen: analytical performance and observations during thrombolytic therapy. | |
Laffan et al. | 17 Investigation of a thrombotic tendency | |
Cellai et al. | Assessment of fibrinolytic activity by measuring the lysis time of a tissue factor-induced clot: a feasibility evaluation | |
Ruberto et al. | Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk. | |
Fritsma | 42 Laboratory Evaluation of Hemostasis | |
JP2007503589A (ja) | 活性化混合物 | |
Fekete et al. | Laboratory modalities for assessing hemostasis during cardiopulmonary bypass | |
Kato et al. | Differences in the composition of activated partial thromboplastin time (APTT) reagents affect clot waveform analysis | |
US11630101B2 (en) | Method for diagnosing anomalies in the coagulation of blood | |
Ibbotson et al. | Thrombin generation and factor VIII: C levels in patients with type 1 diabetes complicated by nephropathy | |
De Metz et al. | Use of a centrifugal analyzer for a chromogenic prothrombin time, a chromogenic activated partial thromboplastin time and a kinetic fibrinogen assay in a routine hospital laboratory | |
Herskovits et al. | Comparison of Russell viper venom–based and activated partial thromboplastin time–based screening assays for resistance to activated protein C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |